MedTrace Logo

Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

NCT02784756 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2022-08-02

No results posted yet for this study

Summary

The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ transplant patients.

Conditions

  • Cytomegalovirus Viraemia

Interventions

DEVICE

Quantiferon-CMV assay

Sponsors & Collaborators

  • Canadian National Transplant Research Program

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Atul Humar, MD · University Health Network, Toronto

  • Deepali Kumar, MD · University Health Network, Toronto

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-02-29
Completion
2020-04-30

Countries

  • Canada
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784756 on ClinicalTrials.gov